Opendata, web and dolomites

HITCHIPDIAG

Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HITCHIPDIAG project word cloud

Explore the words cloud of the HITCHIPDIAG project. It provides you a very rough idea of what is the project "HITCHIPDIAG" about.

basis    platelet    hipa    containing    investors    model    complications    markers    twelve    diagnosis    synthetic    bypass    microarray    strategy    acute    mortality    company    reduce    minutes    microarrays    wellbeing    commercial    glycan    diagnostics    maipa    surgery    syndrome    markets    million    effect    plan    blood    cheaper    faster    surfaces    develops    detected    patient    autoheparin    thrombocytopenia    protocols    suffer    inexpensive    gag    vein    space    antibodies    cardiopulmonary    20    instrument    customers    accuracy    incorporate    dialysis    coronary    standard    adverse    glycosaminoglycan    commercialize    administration    patients    detect    tests    infarction    glycosaminoglycans    grant    automated    specificity    discovered    arrays    erc    organ    yielded    anticoagulant    onto    annually    business    oligosaccharides    dangerous    ip    screen    carbohydrate    deep    diagnostic    assembly    reliabilities    hit    structure    prepare    rapid    printing    heparin    diagnose    thrombosis   

Project "HITCHIPDIAG" data sheet

The following table provides information about the project.

Coordinator
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV 

Organization address
address: HOFGARTENSTRASSE 8
city: MUENCHEN
postcode: 80539
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 147˙094 €
 EC max contribution 147˙094 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) coordinator 147˙094.00

Map

 Project objective

Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans Heparin, a complex glycosaminoglycan (GAG) carbohydrate, is the most commonly used anticoagulant. Twelve million patients in the EU are treated annually for conditions including acute coronary syndrome, deep-vein thrombosis and cardiopulmonary bypass surgery. Heparin-induced thrombocytopenia (HIT) is a dangerous adverse side effect of heparin administration. HIT-II develops after major surgery or dialysis and results in infarction, multi-organ failure and 20% mortality. In Europe 100,000 patients develop HIT-II annually. Currently, two HIT-II diagnostics are available. The HIPA and MAIPA tests detect antibodies against a complex of heparin and platelet factor 4 but suffer from low diagnostic specificity and accuracy. Faster, more reliable and cheaper methods to diagnose complications after administration of heparin are needed to improve patient wellbeing and reduce costs. The ERC Advanced grant AUTOHEPARIN yielded an instrument for the automated assembly of defined oligosaccharides. GAG glycan microarrays were produced by printing GAG oligosaccharides onto surfaces and used to screen patient blood. Specific glycan markers of high diagnostic value were discovered to detected HIT-II within minutes and reliabilities well above existing tests. The overall goal of the project is to establish the business model for a company that will focus on the production of GAG glycan arrays as HIT diagnostic. Specific activities include: 1) Development of standard protocols to detect HIT-II using GAG glycan microarray; 2) Plan and cost structure for GAG arrays production; 3) Analysis of the IP space and development of an IP strategy; 4) Evaluate potential markets and establish basis for commercial discussion with potential customers; 5) Prepare business plan for discussions with investors; 6) Incorporate company to commercialize GAG arrays as HIT diagnostic

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HITCHIPDIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HITCHIPDIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More